BIOCELTIX S.A. ZY -10 Total Liabilities
BIOCELTIX S.A. ZY -10 total liabilities. Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) has total liabilities worth €2.36 Million EUR (≈ $2.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BIOCELTIX S.A. ZY -10 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of BIOCELTIX S.A. ZY -10 (2021–2025)
Total liabilities of BIOCELTIX S.A. ZY -10 from 2021 to 2025. This chart illustrates how BIOCELTIX S.A. ZY -10's total liabilities have evolved over time, based on quarterly financial data.
BIOCELTIX S.A. ZY -10 Competitors by Total Liabilities
The table below lists competitors of BIOCELTIX S.A. ZY -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fima Corporation Bhd
KLSE:3107
|
Malaysia | RM138.86 Million |
|
Right Way Industrial Co Ltd
TW:1506
|
Taiwan | NT$426.92 Million |
|
Hexa Tradex Limited
NSE:HEXATRADEX
|
India | Rs7.50 Billion |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
Thailand | ฿7.80 Billion |
|
Hsinli Chemical Industrial
TWO:4303
|
Taiwan | NT$835.07 Million |
|
Three A Resources Bhd
KLSE:0012
|
Malaysia | RM48.38 Million |
|
Genelux Corporation Common Stock
NASDAQ:GNLX
|
USA | $9.45 Million |
|
CURATIS N AG
SW:CURN
|
Switzerland | CHF9.96 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCELTIX S.A. ZY -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XI3 current and non-current assets.
Liquidity & Leverage Metrics
BIOCELTIX S.A. ZY -10 Total Liabilities Ratios Explained
BIOCELTIX S.A. ZY -10 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 32.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCELTIX S.A. ZY -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCELTIX S.A. ZY -10 (2021–2025)
The table below shows the annual total liabilities of BIOCELTIX S.A. ZY -10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.36 Million ≈ $2.75 Million |
-31.46% |
| 2024-12-31 | €3.44 Million ≈ $4.02 Million |
+51.47% |
| 2023-12-31 | €2.27 Million ≈ $2.65 Million |
-9.35% |
| 2022-12-31 | €2.50 Million ≈ $2.93 Million |
+13.93% |
| 2021-12-31 | €2.20 Million ≈ $2.57 Million |
-- |
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more